The enigma of arsenic carcinogenesis: Role of metabolism

Toxicological Sciences

Volumn 49, Issue 1, 1999, Pages 5-14

  Goering, Peter L ^a,g   Aposhian, H Vasken ^b   Mass, Marc J ^c   Cebrián, Mariano ^d   Beck, Barbara D ^e   Waalkes, Michael P ^f  

^a Ctr Devices Radiological Hlth   (United States)

^b University of Arizona   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d DEPARTAMENTO DE FÍSICA   (Mexico)

^e GRADIENT   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC;

BIOACCUMULATION; BIOTRANSFORMATION; CARCINOGENESIS; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; REVIEW; RISK ASSESSMENT;

ANIMALS; ARSENIC; CARCINOGENS; HUMANS; METHYLTRANSFERASES; ONCOGENES; PHENOTYPE; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 0033040876     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/49.1.5     Document Type: Review

References (58)

1. Agency for Toxic Substances and Disease Registry (1997). Top 20 Hazardous Substances: ATSDR/EPA Priority List for 1997. Http://atsdr1.atsdr.cdc.gov: 8080/cxcx3.html.
2. Aposhian, H. V. (1983). DMSA and DMPS - water soluble antidotes for heavy metal poisoning. Ann. Rev. Pharmacol. Toxicol. 23, 193-215.
3. Aposhian, H. V. (1997). Enzymatic methylation of arsenic species and other approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37, 397-419.
4. Aposhian, H. V., Arroyo, A., Cebrián, M. E., Del Razo, L. M., Hurlbut, K. M., Dart, R. C., Gonzalez-Ramirez, D., Kreppel, H., Speisky, H., Smith, A., Gonsebatt, M. E., Ostrosky-Wegman, P., and Aposhian, M. M. (1997). DMPS-Arsenic challenge test: I. Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J. Pharmacol. Exp. Ther. 282, 192-200.
5. Aposhian, H. V., Maiorino, R. M., Gonzalez-Ramirez, D., Zuniga-Charles, M., Xu, Z., Hurlbut, K. M., Junco-Munoz, P., Cart, R. C., and Aposhian, M. M. (1995). Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 97, 23-38.
6. Aposhian, H. V., Zakharyan, R., Wu, Y., Healy, S., and Aposhian, M. M. (1997). Enzymatic methylation of arsenic compounds: II. An overview. In Arsenic Exposure and Health Effects (C. O. Abernathy, R. L. Calderon, and W. R. Chappell, Eds.), pp. 296-321. Chapman and Hall, New York.
7. Bogdan, G. M., Sampayo-Reyes, A., and Aposhian, H. V. (1994). Arsenic binding proteins of mammalian systems: I. Isolation of three arsenite-binding proteins of rabbit liver. Toxicology 93, 175-193.
8. Buchet, J. P., and Lauwerys, R. (1988). Role of thiols in the in vitro methylation of inorganic arsenic by rat liver cytosol. Biochem. Pharmacol. 37, 3149-3153.
9. Buchet, J. P., Lauwerys, R., and Roels, H. (1981). Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int. Arch. Occup. Env. Health 48, 111-118.
10. Cebrián, M. E., Albores, A., García-Vargas, G., Del Razo, L. M., and Ostrosky-Wegman, P. (1994). Chronic arsenic poisoning in humans: The case of Mexico. In Arsenic in the Environment (J. O. Nriagu, Ed.), Part 11, pp. 93-107. John Wiley and Sons, New York.
11. 3-mduced NB4 apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR-alpha/PML proteins. Blood 88, 1052-1061.
12. Compere, S. J., and Palmiter, R. D. (1981). DNA methylation controls the inducibility of the mouse metallothionein-I gene in lymphoid cells. Cell 25, 233-240.
13. Counts, J. L., and Goodman, J. I. (1995a). Hypomethylation of DNA: An epigenetic mechanism that can facilitate the aberrant oncogene expression involved in liver carcinogenesis. In Liver Regeneration and Carcinogenesis, pp. 227-255. Academic Press, San Diego.
14. Counts, J. L., and Goodman, J. I. (1995b). Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83, 13-15.
15. Del Razo, L. M., García-Vargas, G., Vargas, H., Albores, A., Cebrián, M. E., Gonsebatt, M. E., Montero, R., Ostrosky, P., and Kelch, M. (1995). Chronic high arsenic exposure alters the profile of urinary arsenic metabolites in humans. The Toxicologist 15, 262 (abstract).
16. Del Razo, L. M., García-Vargas, G. G., Vargas, H., Albores, A., Gonsebatt, M. E., Montero, R., Ostrosky-Wegman, P., Kelsh, M., and Cebrián, M. E. (1997). Altered profile of urinary arsenic metabolites in adults with chronic arsenicism: A pilot study. Arch. Toxicol. 71, 211-217.
17. Del Razo, L. M., Hernández, J. L., García-Vargas, G. G., Ostrosky-Wegman, P., de Nava, C. C., and Cebrián, M. E. (1994). Urinary excretion of arsenic species in a human population chronically exposed to arsenic via drinking water: A pilot study. In Arsenic Exposure and Health (W. R. Chappell, C. O. Abernathy, and C. R. Cothern, Eds.), pp. 91-100. Science and Technology Letters, Norwood, England.
18. Farmer, J. G., and Johnson, L. R. (1990). Assessment of occupational exposure to inorganic arsenic based on urinary concentrations and speciation of arsenic. Brit. J. Ind. Med. 47, 342-348.
19. Foa, M., Colombi, A., Maroni, M., Buratti, M., and Calzaferri, G. (1984). The speciation of the chemical forms of arsenic in the biological monitoring of exposure to inorganic arsenic. Sci. Total Environ. 34, 241-259.
20. Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., and Paul, C. L. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U S A. 89, 1827-1831.
21. Guo, H. R. and Valberg, P. A. (1997). Evaluation of the validity of the US EPA's cancer risk assessment for arsenic for low-level exposures: A likelihood ratio approach. Environ. Geochem. Health 19, 133-141.
22. Healy, S. M., Casarez, E. A., Ayala-Fierro, F., and Aposhian, H. V. (1998). Enzymatic methylation of arsenic compounds: V. Arsenite methyltransferase activity in tissues of mice. Toxicol. Appl. Pharmacol. 148, 65-70.
23. Healy, S. M., Zakharyan, R. A., and Aposhian, H. V. (1997). Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat. Res. 386, 229-239.
24. Hopenhayn-Rich, C., Biggs, M. L., Smith, A. H., Kalman, D. A., and Moore, L. E. (1996). Methylation study of a population environmentally exposed to arsenic in drinking water. Environ. Health Perspect. 104, 620-628.
25. Hopenhayn-Rich, C., Biggs, M. L., Smith, A. H., Moore, L. E., and Kalman, D. A. (1995). Arsenic exposure in a chronically exposed population: A multifactorial analysis of metabolite distribution. Presented at the Society for Environmental Geochemistry and Health Second International Conference on Arsenic Exposure and Health Effects. San Diego, CA, June 12-14, 1995.
26. Hopenhayn-Rich, C., Smith, A. H., and Goeden, H. M. (1993). Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ. Res. 60, 161-177.
27. Hseuh, Y. M., Huang, Y. L., Wu, W. L., Huang, C. C., Yang, M. H., Chen, G. S., and Chen, C. J. (1995). Serum β-carotene level, arsenic methylation capability, and risk of skin cancer. Presented at the Society for Environmental Geochemistry and Health Second International Conference on Arsenic Exposure and Health Effects. San Diego, CA, June 12-14, 1995.
28. Hsieh, H. S., and Ganther, H. E. (1977). Biosynthesis of dimethyl selenide from sodium selenite in rat liver and kidney cell-free systems. Biochim. Biophys. Acta 497, 205-17.
29. Hughes, M. F., Menache, M., and Thompson, D. J. (1994). Dose-dependent disposition of sodium arsenate in mice following acute oral exposure. Fundam. Appl. Toxicol. 22, 80-89.
30. Hughes, M. F., and Thompson, D. J. (1996). Subchronic dispositional and toxicological effects of arsenate administered in drinking water to mice. J. Toxicol. Environ. Health 49, 177-196.
31. International Agency for Research on Cancer (IARC) (1987). Arsenic and arsenic compounds. In IARC Monograph on the Evaluation of Carcinogenic Risks to Humans - Overall Evaluations of Carcinogenicity: an Update of IARC Monographs 1 to 42, Suppl. 7, pp. 100-106. IARC, Lyon, France.
32. International Agency for Research on Cancer. (1980). Carcinogenesis of arsenic compounds. In IARC Monograph on Evaluation of Carcinogenic Risk to Humans 23, 37-141. IARC, Lyon,.
33. Kalman, D. A., Hughes, J., van Belle, G., Burbacher, T., Bolgiano, D., Coble, K., Mottet, N. K., and Polissar, L. (1990). The effect of variable environmental arsenic contamination on urinary concentrations of arsenic species. Environ. Health Perspect. 89, 145-151.
34. Leder, A., Pattengale, P. K., Kuo, A., Stewart, T. A., and Leder, P. (1986). Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell 45, 485-495.
35. Mann, S., Droz, P. O., and Vahter, M. (1996). A physiologically based pharmacokinetic model for arsenic exposure: II. Validation and application in humans. Toxicol. Appl. Pharmacol. 140, 471-486.
36. Mass, M. J. (1992). Human Carcinogenesis by arsenic. Environ. Geochem. Health 14, 49-54.
37. Mass, M. J., and Wang, L. (1997). Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: A model for a mechanism of carcinogenesis. Mutat. Res. 386, 263-277.
38. Rudel, R. A., Slayton, T. M., and Beck, B. D. (1996). Implications of arsenic genotoxicity for dose response of carcinogenic effects. Reg. Toxicol. Pharmacol. 23, 87-105.
39. Schroeder, M., and Mass, M. J. (1997). CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem. Biophys. Res. Commun. 235, 403-406.
40. Smith, T. J., Crecelius, E. A., and Reading, J. C. (1977). Airborne arsenic exposure and excretion of methylated arsenic compounds. Environ. Health Perspect. 19, 89-93.
41. Styblo, M., Yamauchi, H., and Thomas, D. J. (1995). Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol. Appl. Pharmacol. 135, 172-78.
42. Thompson, D. J. (1993). A chemical hypothesis for arsenic methylation in mammals. Chem.-Biol. Interact. 88, 89-114.
43. Vahter, M. (1994). Species differences in the metabolism of arsenic In Arsenic: Exposure and Health (W. R. Chappell, C. O. Abernathy, and C. R. Cothern, Eds.), Vol. 40, pp 171-179. Science Reviews Ltd., United Kingdom.
44. Vahter, M., Concha, G., Nermell, B., Nilsson, R., Dulout, F., and Natarajan, A. T. (1996). A unique metabolism of inorganic arsenic in native Andean women. Eur. J. Pharmacol. 293, 455-462.
45. Vahter, M., Couch, R., Nermell, B., and Nilsson, R. (1995). Lack of methylation of inorganic arsenic in the chimpanzee. Toxicol. Appl. Pharmacol. 133, 262-68.
46. Vahter, M., and Marafante, E. (1985). Reduction and binding of arsenate in marmoset monkeys. Arch. Toxicol. 57, 119-124.
47. Vahter, M., and Marafante, E. (1987). Effects of low dietary intake of methionine, choline, or proteins on the biotransformation of arsenite in the rabbit. Toxicol. Lett. 37, 41-46.
48. 74As-arsenite. Arch. Toxicol. 51, 65-77.
49. Valberg, P. A., Beck, B. D., Boardman, P. D., and Cohen, J. T. (1998). Likelihood ratio analysis of skin cancer prevalence associated with arsenic in drinking water in the U.S. Environ. Geochem. Health. 20, 61-66.
50. Wang, Z., and Rossman, T. G. (1996). The carcinogenicity of arsenic. In Toxicology of Metals (L. W. Chang, Ed.), pp. 221-228. CRC Press, Boca Raton.
51. Warner, M. L., Moore, L. E., Smith, M. T., Kalman, D. A., Fanning, E., and Smith, A. H. (1994). Increased micronuclei in exfoliated bladder cells in individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol. Biomarkers Prev. 3, 583-590.
52. Wildfang, E., Zakharyan, R. A., and Aposhian, H. V. (1998). Enzymatic methylation of arsenic compounds: VI. Characterization of hamster liver arsenile and methylarsonic acid methyltransferase activities in vitro. Toxicol. Appl. Pharmacol. 152, 366-375.
53. Yamamoto, S., Konishi, Y., Matsuda, T., Murai, T., Shibata, M., MatusiYuasa, I., Otani, S., Kuroda, K., Endo, G., and Fukushima, S. (1995). Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res. 55, 1271-1276.
54. Yamamura, Y., and Yamauchi, H. (1980). Arsenic metabolites in hair, blood, and urine in workers exposed to arsenic trioxide. Ind. Health 18, 203-210.
55. Yamauchi, H., Takahashi, K., Mashiko, M., and Yamamura, Y. (1989). Biological monitoring of arsenic exposure of gallium arsenide-and inorganic arsenic-exposed workers by determination of inorganic arsenic and its metabolites in urine and hair. Am. Ind. Hyg. Assoc. J. 50, 606-612.
56. Zakharyan, R. A., Wildfang, E., and Aposhian, H. V. (1996). Enzymatic methylation of arsenic compounds: III. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Toxicol. Appl. Pharmacol. 140, 77-84.
57. Zakharyan, R. A., Wu, Y., Bogdan, G. M., and Aposhian, H. V. (1995). Enzymatic methylation of arsenic compounds: I. Assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem. Res. Toxicol. 8, 1029-38.
58. Zhao, C. Q., Young, M. R., Diwan, B. A., Coogan, T. P., and Waalkes, M. P. (1997). Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Nat. Acad. Sci. U S A 94, 10907-10912.